The Ledger

Labcorp agreed to pay $722 million in cash for the clinical, women’s health, urology and corrections testing businesses of OPKO Health’s BioReference unit, with up to $150 million more tied to a prostate cancer test. The deal, announced October 15, includes more than 80 patient service centers and the 4Kscore Test, an FDA-approved blood test that estimates the likelihood of finding aggressive prostate cancer before a biopsy decision. Per the joint Labcorp and OPKO release, as published by Stock Titan, the cash price adjusts up or down with closing revenues, the earnout depends on 4Kscore revenue, and Labcorp expects about $250 million in revenue from the acquired business in the first year after closing. Regulatory approvals are required, no closing date is given, and both companies operate independently until then. The earnout thresholds and measurement period are not disclosed. This is the third BioReference carve-out Labcorp has made: it announced the general diagnostics purchase in 2024 (Labcorp release) and completed the oncology purchase in 2025 (Labcorp release). Who it hits: independent and hospital-outreach laboratories competing for physician and correctional-health contracts, since the largest national lab keeps absorbing a regional rival piece by piece. Confidence: High on the announced terms; Low on whether regulators take a second look at the cumulative result. The primary Labcorp investor page blocked our fetch this run, so the figures rest on the wire copy of the release.

Rush University System for Health and Endeavor Health plan to merge into a 12-hospital Chicago-area system with nearly $11 billion in annual revenue, and neither side is in distress. Announced October 14, the combined system would carry the Rush name, run 400 outpatient clinics, employ more than 46,000 people and serve more than 2 million patients a year in Northern Illinois and Northwest Indiana, per Healthcare Dive and Fierce Healthcare, both supplemental; the systems’ own release was not retrieved. Rush reported net income of $294 million for the 12 months ended June 30, up 57%. Endeavor, the third-largest system in Illinois, reported net income above $663 million in its latest fiscal year, per Becker’s Hospital Review as relayed by Healthcare Dive. Endeavor has committed $1 billion to research, community care and quality programs, and the board would split evenly between the two sides under a Rush chair. Close is expected in early 2027, pending regulatory review. Who it hits: Northwestern Medicine, University of Chicago Medicine and Advocate Health, and every Chicago-area payer negotiating rates, since a profitable merger of equals is a scale play, not a rescue. Confidence: High on the announcement; Med on the revenue figure, which is press-reported rather than audited.

Individual health insurance enrollment fell 18% in a year, from 25.2 million people in June 2025 to 20.5 million in June 2026, KFF estimates. The KFF analysis, published October 14, says the loss of more than 4.6 million people covers both on- and off-exchange plans, which are about nine in ten Obamacare Marketplace members. KFF ties the drop to expiration of the enhanced premium tax credits, other policy changes and nonpayment, and notes Marketplace enrollment fell in every state except New Mexico. The Congressional Budget Office projected a drop of roughly 25% through 2026, so the observed decline is closing in on that forecast. Insurers have proposed a median 15% premium increase for 2027, and cancellations announced after June are not in these figures. Who it hits: insurers with large exchange books and hospitals in states with high uninsured growth, because fewer covered lives and rising premiums raise bad debt and tilt the risk pool sicker. Confidence: High on the KFF figures; Low on how the 2027 open enrollment season changes them.

H1, an artificial intelligence (AI) platform that helps drugmakers and health plans find the right doctors, acquired Defacto Health, a data company that tracks payer networks and which providers accept which plans. The Healthcare IT Today report, dated October 15, says financial terms were not disclosed. Health plans use Defacto’s data to check provider directory accuracy, find clusters of errors and benchmark their networks, and its two co-founders, who previously led provider-data work at CAQH, join H1 to run the combined effort. Who it hits: health plans facing directory-accuracy rules and the vendors that sell them cleanup tools. Confidence: Med. This is trade press only; the company release was not retrieved, and the article’s note that the deal was first announced September 9 is unverified.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
BioReference Health clinical, women’s health, urology and corrections testing businesses, 80+ patient service centers, 4Kscore Test	Labcorp	Clinical laboratories	$722 million cash plus up to $150 million earnout; regulatory approval required	Labcorp and OPKO release (Stock Titan copy)
Endeavor Health	Rush University System for Health (merger of equals)	Nonprofit health system merger	No price; combined revenue near $11 billion (press-reported); close expected early 2027	Healthcare Dive, supplemental
Defacto Health	H1	Provider and payer network data	Not disclosed	Healthcare IT Today, supplemental